VAXCYTE INC (PCVX) Stock News
NASDAQ:PCVX - Nasdaq - US92243G1085 - Common Stock - Currency: USD
PCVX Latest News, Press Relases and Analysis
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity...
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care.
The Senate will vote Thursday on whether to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks.
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
-- Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to Announce VAX-31 Infant...
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
SAN CARLOS, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity...
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX)...
1 Vanguard Index Fund to Buy to Beat the S&P 500 in 2025, According to a Wall Street Bank
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026,...
1 Vanguard Index Fund May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
-- VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of...
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate...
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering...
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering...
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering...
Vaccine Maker Vaxcyte Offers $1 Billion in Shares, Warrants
Vaxcyte Inc., a clinical stage vaccine company, is seeking to raise $1 billion by selling shares and pre-funded warrants after the company reported data from a recent study, sending the stock surging.
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering...
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
Tuesday, Vaxcyte, Inc. (NASDAQ:PCVX) released topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the company's 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease. VAX-31 was well tolerated and demonstrated a safety profile at all doses studied through the full six-month evaluation period, similar to Pfizer Inc's (NYSE:PFE) Prevnar 20 (PCV20). VAX-31 showed robust opsonophagocytic activ
Mentions: PFE
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market
The company is looking to take on Pfizer in the massive pneumococcal conjugate vaccine market.
Mentions: PFE
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
-- At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity Immune Responses for All 31 Serotypes -- -- At Middle and High Doses, VAX-31...